Roche's Alecensa nabbed a new FDA approval to treat first-line lung cancer, putting it on even footing with Pfizer's Xalkori and Novartis'…
Allergan is facing allegations it betrayed shareholder interests by not disclosing details about generic price hikes.
Novartis is blazing ahead with its bid to take its CAR-T therapy Kymriah into new realms with a double-pronged application in Europe.
Teva, the world's largest generics maker, is looking to form a Chinese joint venture with local company Guangzhou Pharma.
AbbVie took a big step toward putting investors’ minds at ease about aging blockbuster Humira, with better-than-expected third-quarter results.
Novartis investors were disappointed when CEO Joe Jimenez said that a decision about eye unit Alcon would be delayed.
Still struggling to turn its manufacturing around, Dr. Reddy's is recalling 569,000 store-brand famotidine tablets in the U.S.
Merck & Co. plans to jettison three U.S. sales teams and 1,800 associated staffers while creating a new, 960-employee chronic care force.
With an FDA committee nod, Novo Nordisk is one step closer to rolling out its key diabetes drug semaglutide—and launch preps are underway.
What comes after a successful M&A hunt at Gilead Sciences? A promotion for the executive who sewed up its $11.9 billion deal for Kite Pharma.